Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Autotransplant conditioning regimens for aggressive lymphoma: are we on the right road?

Bone Marrow Transplantation volume 40, pages 505–513 (2007)Cite this article

Abstract

High-dose chemotherapy and autologous stem cell transplant (ASCT) is the standard approach for chemosensitive, relapsed aggressive non-Hodgkin's lymphoma (NHL). Various conditioning regimens have been used as treatment before ASCT and disease-free (DFS) and overall survival (OS) rates range from 34 to 60% and 26 to 46%, respectively. To date, few comparative randomized trials have been performed and no regimen has demonstrated superiority to another. Reduction of disease relapse remains the major hurdle for improving patient outcome and in vitro and in vivo purging of lymphoma cells has not necessarily enhanced results. Rituximab pre-mobilization and post-transplant appear to provide better response rates with OS approaching 87–91% at 2–3 years. Newer approaches with radioimmunotherapy may raise DFS to 78% and OS to 93%, albeit with short follow-up. Advances in the conditioning regimens and supportive care have reduced transplant-related mortality to less than 10%. In this review we discuss commonly utilized conditioning regimens, describe their pros and cons and address purging and present conditioning strategies. Owing to the poor outcome with conventional chemotherapy in mantle cell, Burkitt's and T-cell lymphoma, we propose the standard approach of front-line ASCT for these high-risk lymphoma patients. Finally, we will present novel strategies, which can enhance the anti-lymphoma effect, at the same time reducing toxicity, to improve the outcome of ASCT in NHL patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545.

    Article  CAS  PubMed  Google Scholar 

  2. Guglielmi C, Gomez F, Philip T, Hagenbeek A, Martelli M, Sebban C et al. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. J Clin Oncol 1998; 16: 3264–3269.

    Article  CAS  PubMed  Google Scholar 

  3. Friedberg JW, Neuberg D, Stone RM, Alyea E, Jallow H, LaCasce A et al. Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3128–3135.

    Article  CAS  PubMed  Google Scholar 

  4. Milligan DW, Ruiz De Elvira MC, Kolb HJ, Goldstone AH, Meloni G, Rohatiner AZ et al. Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from the EBMT. EBMT lymphoma and late effects working parties. European Group for Blood and Marrow Transplantation. Br J Haematol 1999; 106: 1020–1026.

    Article  CAS  PubMed  Google Scholar 

  5. Caballero MD, Rubio V, Rifon J, Heras I, Garcia-Sanz R, Vazquez L et al. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant 1997; 20: 451–458.

    Article  CAS  PubMed  Google Scholar 

  6. de Magalhaes-Silverman M, Lister J, Rybka W, Wilson J, Ball E . Busulfan and cyclophosphamide (BU/CY2) as preparative regimen for patients with lymphoma. Bone Marrow Transplant 1997; 19: 777–781.

    Article  CAS  PubMed  Google Scholar 

  7. Fernandez HF . The Use of Intravenous Busulfan and Cyclophosphamide as a Conditioning Regimen for Non-Hodgkin's Lymphoma. ASBMT/CIBMTR Tandem Meetings. Honolulu, HI, 2006.

    Google Scholar 

  8. Hanel M, Kroger N, Sonnenberg S, Bornhauser M, Kruger W, Kroschinsky F et al. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma. Ann Hematol 2002; 81: 96–102.

    Article  CAS  PubMed  Google Scholar 

  9. Schiffman KS, Bensinger WI, Appelbaum FR, Rowley S, Lilleby K, Clift RA et al. Phase II study of high-dose busulfan, melphalan and thiotepa with autologous peripheral blood stem cell support in patients with malignant disease. Bone Marrow Transplant 1996; 17: 943–950.

    CAS  PubMed  Google Scholar 

  10. Stein RS, Greer JP, Goodman S, Brandt SJ, Morgan DS, Macon WR et al. Intensified preparative regimens and autologous transplantation in refractory or relapsed intermediate grade non-Hodgkin's lymphoma. Bone Marrow Transplant 2000; 25: 257–262.

    Article  CAS  PubMed  Google Scholar 

  11. Stiff PJ, Dahlberg S, Forman SJ, McCall AR, Horning SJ, Nademanee AP et al. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens – a Southwest Oncology Group trial. J Clin Oncol 1998; 16: 48–55.

    Article  CAS  PubMed  Google Scholar 

  12. Wadhwa PD, Fu P, Koc ON, Cooper BW, Fox RM, Creger RJ et al. High-dose carmustine, etoposide, and cisplatin for autologous stem cell transplantation with or without involved-field radiation for relapsed/refractory lymphoma: an effective regimen with low morbidity and mortality. Biol Blood Marrow Transplant 2005; 11: 13–22.

    Article  CAS  PubMed  Google Scholar 

  13. Gianni AM, Bregni M, Siena S, Brambilla C, Di Nicola M, Lombardi F et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-Cell lymphoma. N Engl J Med 1997; 336: 1290–1298.

    Article  CAS  PubMed  Google Scholar 

  14. Blay J, Gomez F, Sebban C, Bachelot T, Biron P, Guglielmi C et al. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group. Blood 1998; 92: 3562–3568.

    CAS  PubMed  Google Scholar 

  15. Leonard BM, Hetu F, Busque L, Gyger M, Belanger R, Perreault C et al. Lymphoma cell burden in progenitor cell grafts measured by competitive polymerase chain reaction: less than one log difference between bone marrow and peripheral blood sources. Blood 1998; 91: 331–339.

    CAS  PubMed  Google Scholar 

  16. Gribben JG, Freedman AS, Neuberg D, Roy DC, Blake KW, Woo SD et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 1991; 325: 1525–1533.

    Article  CAS  PubMed  Google Scholar 

  17. Galimberti S, Marasca R, Caracciolo F, Fazzi R, Papineschi F, Benedetti E et al. The role of molecular monitoring in autotransplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant 2002; 29: 581–587.

    CAS  PubMed  Google Scholar 

  18. Blystad A, Kvalheim G, Torlakovic E, Holte H, Jacobsen E, Beiske K et al. High-dose therapy supported with immunomagnetic purged autologous bone marrow in high-grade B-cell non-Hodgkin's lymphoma. Bone Marrow Transplant 1999; 24: 865–872.

    Article  CAS  PubMed  Google Scholar 

  19. van Heeckeren WJ, Vollweiler J, Fu P, Cooper BW, Meyerson H, Lazarus HM et al. Randomised comparison of two B-cell purging protocols for patients with B-cell non-Hodgkin lymphoma: in vivo purging with rituximab versus ex vivo purging with CliniMACS CD34 cell enrichment device. Br J Haematol 2006; 132: 42–55.

    Article  PubMed  Google Scholar 

  20. Williams CD, Goldstone AH, Pearce RM, Philip T, Hartmann O, Colombat P et al. Purging of bone marrow in autologous bone marrow transplantation for non-Hodgkin's lymphoma: a case-matched comparison with unpurged cases by the European Blood and Marrow Transplant Lymphoma Registry. J Clin Oncol 1996; 14: 2454–2464.

    Article  CAS  PubMed  Google Scholar 

  21. Cilley J, Winter JN . Radioimmunotherapy and autologous stem cell transplantation for the treatment of B-cell lymphomas. Haematologica 2006; 91: 114–120.

    CAS  PubMed  Google Scholar 

  22. Hoerr AL, Gao F, Hidalgo J, Tiwari D, Blum KA, Mathews V et al. Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's lymphoma. J Clin Oncol 2004; 22: 4561–4566.

    Article  CAS  PubMed  Google Scholar 

  23. Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Fisher RI . Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 2005; 46: 1569–1573.

    Article  CAS  PubMed  Google Scholar 

  24. Flinn IW, O'Donnell PV, Goodrich A, Vogelsang G, Abrams R, Noga S et al. Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2000; 6: 628–632.

    Article  CAS  PubMed  Google Scholar 

  25. Khouri IF, Saliba RM, Hosing C, Okoroji G-J, Acholonu S, Anderlini P et al. Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-hodgkin's lymphomas. J Clin Oncol 2005; 23: 2240–2247.

    Article  CAS  PubMed  Google Scholar 

  26. Press OW, Eary JF, Appelbaum FR, Martin PJ, Badger CC, Nelp WB et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993; 329: 1219–1224.

    Article  CAS  PubMed  Google Scholar 

  27. Press OW, Eary JF, Appelbaum FR, Martin PJ, Nelp WB, Glenn S et al. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B-cell lymphomas. Lancet 1995; 346: 336–340.

    Article  CAS  PubMed  Google Scholar 

  28. Press OW, Eary JF, Gooley T, Gopal AK, Liu S, Rajendran JG et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 2000; 96: 2934–2942.

    CAS  PubMed  Google Scholar 

  29. Vose JM, Bierman PJ, Enke C, Hankins J, Bociek G, Lynch JC et al. Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 461–467.

    Article  CAS  PubMed  Google Scholar 

  30. Nademanee A, Forman S, Molina A, Fung H, Smith D, Dagis A et al. A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood 2005; 106: 2896–2902.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Fung HC, Forman SJ, Nademanee A, Molina D, Yamauchi R, Speilberger N et al. A new preparative regimen for older patients with aggressive CD20-positive B-cell lymphoma utilizing standard-dose yttrium-90 Ibritumomab Tiuxetan (Zevalin) radioimmunotherapy (RIT) combined with high-dose BEAM followed by autologous hematopoietic cell transplantation (AHCT): targeted intensification without increased transplant-related toxicity. ASH Annu Meeting Abstr 2003; 102: 248a. Abstract #870.

    Google Scholar 

  32. Winter JN, Inwards D, Spies S, Wiseman G, Patton D, Erwin W et al. 90Y Ibritumomab Tiuxetan (Zevalin(R); 90YZ) doses calculated to deliver up to 1500 cGy to critical organs may be safely combined with high-dose BEAM and autotransplant in NHL. ASH Annu Meeting Abstr 2006; 108: 330.

    Google Scholar 

  33. Flohr T, Hess G, Kolbe K, Gamm H, Nolte H, Stanislawski T et al. Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy in B-NHL. Bone Marrow Transplant 2002; 29: 769–775.

    Article  CAS  PubMed  Google Scholar 

  34. Haioun C, Lepage E, Gisselbrecht C, Salles G, Coiffier B, Brice P et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol – a groupe d'Etude des lymphomes de l'Adulte study. J Clin Oncol 2000; 18: 3025–3030.

    Article  CAS  PubMed  Google Scholar 

  35. Santini G, Salvagno L, Leoni P, Chisesi T, De Souza C, Sertoli MR et al. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's lymphoma cooperative study group. J Clin Oncol 1998; 16: 2796–2802.

    Article  CAS  PubMed  Google Scholar 

  36. Milpied N, Deconinck E, Gaillard F, Delwail V, Foussard C, Berthou C et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004; 350: 1287–1295.

    Article  CAS  PubMed  Google Scholar 

  37. Khouri IF, Romaguera J, Kantarjian H, Palmer JL, Pugh WC, Korbling M et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 1998; 16: 3803–3809.

    Article  CAS  PubMed  Google Scholar 

  38. Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005; 23: 7013–7023.

    Article  CAS  PubMed  Google Scholar 

  39. Magrath I, Adde M, Shad A, Venzon D, Seibel N, Gootenberg J et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 1996; 14: 925–934.

    Article  CAS  PubMed  Google Scholar 

  40. Schwenn MR, Blattner SR, Lynch E, Weinstein HJ . HiC-COM: a 2-month intensive chemotherapy regimen for children with stage III and IV Burkitt's lymphoma and B-cell acute lymphoblastic leukemia. J Clin Oncol 1991; 9: 133–138.

    Article  CAS  PubMed  Google Scholar 

  41. Sweetenham JW, Pearce R, Taghipour G, Blaise D, Gisselbrecht C, Goldstone AH . Adult Burkitt's and Burkitt-like non-Hodgkin's lymphoma – outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: results from the European Group for Blood and Marrow Transplantation. J Clin Oncol 1996; 14: 2465–2472.

    Article  CAS  PubMed  Google Scholar 

  42. Sweetenham JW, Santini G, Qian W, Guelfi M, Schmitz N, Simnett S et al. High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group. J Clin Oncol 2001; 19: 2927–2936.

    Article  CAS  PubMed  Google Scholar 

  43. Levine JE, Harris RE, Loberiza Jr FR, Armitage JO, Vose JM, Van Besien K et al. A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma. Blood 2003; 101: 2476–2482.

    Article  CAS  PubMed  Google Scholar 

  44. Blystad AK, Enblad G, Kvaloy S, Berglund A, Delabie J, Holte H et al. High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas. Bone Marrow Transplant 2001; 27: 711–716.

    Article  CAS  PubMed  Google Scholar 

  45. Rodriguez J, Caballero MD, Gutierrez A, Gandarillas M, Sierra J, Lopez-Guillermo A et al. High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience. Haematologica 2003; 88: 1372–1377.

    CAS  PubMed  Google Scholar 

  46. Rodriguez J, Caballero MD, Gutierrez A, Marin J, Lahuerta JJ, Sureda A et al. High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience. Ann Oncol 2003; 14: 1768–1775.

    Article  CAS  PubMed  Google Scholar 

  47. Younes A, Preti HA, Hagemeister FB, McLaughlin P, Romaguera JE, Rodriguez MA et al. Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. Ann Oncol 2001; 12: 923–927.

    Article  CAS  PubMed  Google Scholar 

  48. Muller-Beissenhirtz H, Kasper C, Nuckel H, Duhrsen U . Gemcitabine, vinorelbine and prednisone for refractory or relapsed aggressive lymphoma, results of a phase II single center study. Ann Hematol 2005; 84: 796–801.

    Article  PubMed  Google Scholar 

  49. Morschhauser F, Leonard JP, Fayad L, Coiffier B, Schuster SJ, Dyer MJS et al. Rituximab-relapsing patients with non-hodgkins lymphoma respond even at lower doses of humanized anti-CD20 antibody, IMMU-106 (hA20): phase I/II results. ASH Annu Meeting Abstr 2006; 108: 2719.

    Google Scholar 

  50. Stein R, Qu Z, Chen S, Rosario A, Shi V, Hayes M et al. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Clin Cancer Res 2004; 10: 2868–2878.

    Article  CAS  PubMed  Google Scholar 

  51. Salven P, Orpana A, Teerenhovi L, Joensuu H . Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients. Blood 2000; 96: 3712–3718.

    CAS  PubMed  Google Scholar 

  52. Ganjoo KN, An CS, Robertson MJ, Gordon LI, Sen JA, Weisenbach J et al. Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis. Leuk Lymphoma 2006; 47: 998–1005.

    Article  CAS  PubMed  Google Scholar 

  53. Verhelle D, Corral LG, Wong K, Mueller JH, Moutouh-de Parseval L, Jensen-Pergakes K et al. Lenalidomide and CC-4047 inhibit the proliferation of malignant B-cells while expanding normal CD34+ progenitor cells. Cancer Res 2007; 67: 746–755.

    Article  CAS  PubMed  Google Scholar 

  54. Hake CR, Graubert TA, Fenske TS . Does autologous transplantation directly increase the risk of secondary leukemia in lymphoma patients? Bone Marrow Transplant 2007; 39: 59–70.

    Article  CAS  PubMed  Google Scholar 

  55. Krishnan A, Bhatia S, Slovak ML, Arber DA, Niland JC, Nademanee A et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood 2000; 95: 1588–1593.

    CAS  PubMed  Google Scholar 

  56. Douglas S, Smith C, McFarland R, Badel K, Calandra G . AMD3100 with G-CSF for autologous peripheral blood progenitor cell (PBPC) mobilization in non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM): mobilization, engraftment, and pharmacokinetics (PK). ASH Annual Meeting Abstracts 2006; 108: 3383.

    Google Scholar 

  57. Srivastava A, Poonkuzhali B, Shaji RV, George B, Mathews V, Chandy M et al. Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. Blood 2004; 104: 1574–1577.

    Article  CAS  PubMed  Google Scholar 

  58. Lien S, Larsson AK, Mannervik B . The polymorphic human glutathione transferase T1-1, the most efficient glutathione transferase in the denitrosation and inactivation of the anticancer drug 1, 3-bis(2-chloroethyl)-1-nitrosourea. Biochem Pharmacol 2002; 63: 191–197.

    Article  CAS  PubMed  Google Scholar 

  59. Petros WP, Hopkins PJ, Spruill S, Broadwater G, Vredenburgh JJ, Colvin OM et al. Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer. J Clin Oncol 2005; 23: 6117–6125.

    Article  CAS  PubMed  Google Scholar 

  60. Filicko J, Lazarus HM, Flomenberg N . Mucosal injury in patients undergoing hematopoietic progenitor cell transplantation: new approaches to prophylaxis and treatment. Bone Marrow Transplant 2003; 31: 1–10.

    Article  CAS  PubMed  Google Scholar 

  61. Anaissie E, Schuster M, Hurd D . A phase II, multicenter, randomized, double-blind, placebo-controlled trial of the safety and efficacy of velafermin (CG53135-05) administered intravenously as a single dose for the prevention of oral mucositis in patients receiving autologous hematopoietic stem cell transplant (AHSCT). Biol Blood Marrow Transplant 2006; 12: 21.

    Article  Google Scholar 

  62. Stiff PJ, Emmanouilides C, Bensinger WI, Gentile T, Blazar B, Shea TC et al. Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting. J Clin Oncol 2006; 24: 5186–5193.

    Article  CAS  PubMed  Google Scholar 

  63. Dall'Ozzo S, Tartas S, Paintaud G, Cartron G, Colombat P, Bardos P et al. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 2004; 64: 4664–4669.

    Article  CAS  PubMed  Google Scholar 

  64. Holmberg LA, Maloney D, Bensinger W . Immunotherapy with rituximab/interleukin-2 after autologous stem cell transplantation as treatment for CD20+ non-Hodgkin's lymphoma. Clin Lymphoma Myeloma 2006; 7: 135–139.

    Article  CAS  PubMed  Google Scholar 

  65. Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P et al. The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007; 109: 1857–1861.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Blood and Marrow Transplant, Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL, USA

    H F Fernandez

  2. Department of Medicine, Division of Hematology/Oncology, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, USA

    M P Escalón & D Pereira

  3. Comprehensive Cancer Center of Case Western Reserve University, University Hospitals of Cleveland, Cleveland, OH, USA

    H M Lazarus

Authors
  1. H F Fernandez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M P Escalón
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D Pereira
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H M Lazarus
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H F Fernandez.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fernandez, H., Escalón, M., Pereira, D. et al. Autotransplant conditioning regimens for aggressive lymphoma: are we on the right road?. Bone Marrow Transplant 40, 505–513 (2007). https://doi.org/10.1038/sj.bmt.1705744

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705744

Keywords

This article is cited by

Search

Advanced search

Quick links